Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: A retrospective multicentre study

Human Reproduction

Volumn 28, Issue 9, 2013, Pages 2529-2536

  Iliodromiti, Stamatina ^a   Blockeel, Christophe ^b   Tremellen, Kelton P ^c   Fleming, Richard ^a   Tournaye, Herman ^b   Humaidan, Peter ^d   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

clinical pregnancy; GnRH agonist; GnRH antagonist; luteal support; ovarian hyperstimulation syndrome

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTRADIOL VALERATE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; VALERIC ACID;

ADULT; ARTICLE; CORPUS LUTEUM; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR ASPIRATION; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY HYPERSTIMULATION; PREGNANCY RATE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL PREGNANCY; GNRH AGONIST; GNRH ANTAGONIST; LUTEAL SUPPORT; OVARIAN HYPERSTIMULATION SYNDROME;

ADULT; BELGIUM; COHORT STUDIES; CORPUS LUTEUM; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; GREAT BRITAIN; HUMANS; INCIDENCE; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOUTH AUSTRALIA;

EID: 84883136841     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det304     Document Type: Article

References (39)

1. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644-1653, e1641.
2. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T. Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21:1260-1265.
3. Belva F, Henriet S, Van den Abbeel E, Camus M, Devroey P, Van der Elst J, Liebaers I, Haentjens P, Bonduelle M. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008;23:2227-2238.
4. de Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V, Kupka M, Nygren KG, Andersen AN, Eshre. Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod 2010;25:1851-1862.
5. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012;97:561-571.
6. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
7. Galindo A, Bodri D, Jose Guillen J, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 2009;25:60-66.
8. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotrophin-releasing hormone agonist to trigger follicular maturation for in-vitro fertilization. J Clin Endocrinol Metab 1990;71:918-922.
9. Henningsen A-KA, Pinborg A, Lidegaard O, Vestergaard C, Forman JL, Andersen AN. Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception: Danish national sibling-cohort study. Fertil Steril 2011;95:959-963.
10. Hoff JD, Quigley ME, Yen SSC. Hormonal dynamics at midcycle-a réévaluation. J Clin Endocrinol Metab 1983;57:792-796.
11. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18:630-634.
12. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213-1220. (Pubitemid 40796107)
13. Humaidan P, Bungum L, Bungum M, Andersen CY. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13:173-178. (Pubitemid 44207763)
14. Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY. 1500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010a; 93:847-854.
15. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010b; 94:389-400.
16. Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel L, Devroey P, Fatemi H. Endometrial gene expression in the early luteal phase is impacted by mode oftriggeringfinal oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles. Hum Reprod 2012;27:3259-3272.
17. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511-2521.
18. Itskovitz J, Erlik Y, Boldes R, Kahana L, Levron J, Brandes JM. Induction of preovulatory luteinizing-hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing-hormone agonist. Fertil Steril 1991;56:213-220.
19. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20:2887-2892. (Pubitemid 41508652)
20. Lawlor DA, Nelson SM. Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lancet 2012;379:521-527.
21. Maheshwari A, Bhattacharya S. Elective frozen replacement cycles for all: ready for prime time? Hum Reprod 2013;28:6-9.
22. Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2012;98:368-377, e1-9.
23. Mathur RS, Akande AV, Keay SD, Hung LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:901-907. (Pubitemid 30227512)
24. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, Pellicer A, Remohi J. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessorblind study. Reprod Biomed Online 2009;19:486-492.
25. Muñoz M, Cruz M, Humaidan P, Garrido N, Pérez-Cano I, Meseguer M. The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study. Eur J Obstet Gynecol Reprod Biol 2013;168:167-172.
26. Nelson SM. Antimullerian hormone: is the writing on the wall for antral follicle count? Fertil Steril 2013;99:1563-1564.
27. Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144, 018 treatment cycles. PLoS Med 2011;8:e1000386.
28. NICE. Fertility: Assessment and Treatment for People with Fertility Problems. London: National Institute for Health and Care Excellence, 2013.
29. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005;20:636-641. (Pubitemid 40425488)
30. Pinborg A. To transfer fresh or thawed embryos? Semin Reprod Med 2012; 30:230-235.
31. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011;26:3437-3442.
32. Raine-Fenning N, Jayaprakasan K, Deb S, Clewes J, Joergner I, Dehghani Bonaki S, Johnson I. Automated follicle tracking improves measurement reliability in patients undergoing ovarian stimulation. Reprod Biomed Online 2009;18:658-663.
33. RCOG. The Management of Ovarian Hyperstimulation Syndrome. London: Royal College of Obstetricians and Gynaecologists, 2006.
34. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU h CG. Hum Reprod 2013;28:2522-2528.
35. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M Hudson C. Matched-cohort comparison of single-embryo transfers in fresh and frozen-thawed embryo transfer cycles. Fertil Steril 2013; 99:389-392.
36. Sismanoglu A, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet 2009; 26:251-256.
37. Tomas C, Alsbjerg B, Martikainen H, Humaidan P. Pregnancy loss after frozen-embryo transfer-a comparison of three protocols. Fertil Steril 2012;98:1165-1169.
38. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, Khattab SM, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev (Online) 2011;CD008046.
39. Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online 2012;24:281-292.